ALFA Finder| Revenue growth | H1 total income +19%; Q2 +14% YoY. |
|---|---|
| Margins | Care CIS ratio 100.5%, 70bps YoY improvement. |
| Demand visibility | Care GWP +35%; Finvest lending restarted 6 Nov. |
Growth
H1 total income +19% YoY (Rs4,717 Cr); Q2 +14%. Care GWP Rs6,897 Cr (+35%), PBT Rs392 Cr (+42%).
Outlook
No quantified guidance. Finvest expanding to Tamil Nadu, Maharashtra, Rajasthan; REL Rs250 Cr RHDFCL capital commitment.
Risks
Consolidated H1 loss; RBL profitability weak in tough market; RHDFCL losses; Finvest lending only restarted 6 Nov.
Last quarter's promises, checked
Delivered
- Guided Finvest lending restart in ~3-4 months (13 Aug call) → restarted 6 Nov 2026, ~2.8 months (= BEAT)
Partly delivered
- Guided Care combined ratio to 100% within 2 years (CISR 102.7% in Q1) → CIS ratio 100.5% in Q2 (= PARTIAL, on trajectory)
- Guided Care Rs200 Cr sub-debt (Aug 2026) → Rs450 Cr Tier II reported; instrument match unverified (= PARTIAL)
Investor Presentation filed with NSE, NSE: RELIGARE. Summary written with AI assistance from the document.
Religare Enterprises Ltd: key numbers
- Share price
- ₹233.93
- Market cap
- ₹8,065 Cr
- Revenue (annual)
- ₹8,459 Cr
- Net profit (annual)
- ₹85.96 Cr
- P/E (TTM)
- -238.1×Sector 21.0×
- Promoter holding
- 31.26%+0.70% QoQ
- FII holding
- 9.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Religare Enterprises Ltd
All →Religare Enterprises Other Announcement
Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.
Religare Enterprises Earnings Call Transcript: Key Takeaways
Consolidated H1 loss of ₹145 Cr persists; profit rests on Care Health's Ind AS PBT (₹392 Cr, +42%) while NBFC and broking remain small and in build-out.
Religare Enterprises Q2 FY27 Results: Net Loss of ₹97.7 Cr
Religare Enterprises Ltd reported revenue from operations of ₹2,381 Cr (+14.6% YoY) and a net loss of ₹97.7 Cr for Q2 FY27.
- Key figure
- Net loss ₹97.7 Cr
Religare Enterprises Employee Stock Options
Religare Enterprises' NRC granted 25,998 stock options under its ESOP 2019 scheme. Options vest in 5 equal annual tranches at Rs. 230.78 per share exercise price.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Religare Enterprises Board Meeting Date
Religare Enterprises intimated a board meeting on November 12, 2026 to consider unaudited standalone and consolidated results for the quarter ended September 30, 2026. The trading window stays closed until November 14, 2026.